Posology : מינונים

4.2 Posology and method of administration
Zomacton therapy should be used only under the supervision of a qualified physician experienced in the management of patients with growth hormone deficiency.
The dosage of administration of Zomacton should be individualised for each patient.
The duration of treatment, usually a period of several years will depend on maximum achievable therapeutic benefit.
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. Therefore, injection sites should be alternated.
Growth Hormone Deficiency
Generally a dose of 0.17 – 0.23 mg/kg bodyweight (approximating to 4.9 mg/m2 – 6.9 mg/m2 body surface area) per week divided into 6 - 7 S.C. injections is recommended (corresponding to a daily injection of 0.02 – 0.03 mg/kg bodyweight or 0.7 – 1.0 mg/m2 body surface area).
The total weekly dose of 0.27 mg/kg or 8 mg/m2 body surface area should not be exceeded (corresponding to daily injections of up to about 0.04 mg/kg).
Turner’s Syndrome
Generally a dose of 0.33 mg/kg/bodyweight (approximating to 9.86 mg/m2/body surface area) per week divided into 6 - 7 S.C.. injections are recommended (corresponding to daily injection of 0.05 mg/kg/bodyweight or 1.40-1.63 mg/m2/body surface area).
Instructions for preparation, see section 6.6.
Administration
The required dose of ZOMACTON is administered with a ZOMAJET needle-free device or with an ordinary syringe.
Specific instructions for the use of the ZOMAJET device are given in a booklet supplied with the device.